Measurement of Serum Chemerin and Deoxypyridinoline Levels in Iraqi ‎Osteoporotic ‎Postmenopausal Women with and without Metabolic Syn-drome

Abstract

Metabolic syndrome is a cluster of medical conditions composed of ‎abdominal obesity, ‎hyperglycemia, hypertension, and lipid abnormalities, in which ‎each can affect bone in ‎different ways. We examine ‎the association between metabolic syndrome and metabolic bone disease ‎‎(osteoporosis) by ‎measuring adipose tissue marker (chemerin) and bone resorption ‎marker ‎‎(deoxypyridinoline) in ‎the serum of osteoporotic postmenopausal women with ‎and without ‎metabolic syndrome. ‎ A case-control study included 112 postmenopausal women from 51 to 67 years of ‎age. ‎Women were ‎selected from Osteoporosis Clinic- Al Yarmouk Teaching ‎Hospital and were ‎divided into two ‎groups: group (1)- patients group included 57 ‎postmenopausal women with ‎osteoporosis (35 ‎osteoporotic women with metabolic ‎syndrome and 22 osteoporotic women ‎without metabolic ‎syndrome) and group ‎‎(2)-control group included 55 postmenopausal women ‎without ‎osteoporosis and ‎metabolic syndrome. A serum sample was taken from each woman and ‎analysed ‎for ‎assessing chemerin, deoxypyridinoline, fasting serum glucose, and lipid profile. We found ‎a significant increase (p-value<0.001) in the mean value of serum chemerin ‎and ‎deoxypyridinoline ‎levels in patients compared to controls. ‎In ‎conclusion, chemerin is an adipose tissue marker associated with metabolic syndrome ‎and ‎may ‎have an impact on bone turn over and development of metabolic bone ‎disease ‎which ‎enhanced by the strong positive correlation between chemerin and bone ‎resorption ‎marker ‎‎(deoxypyridinoline).